Axonics, Inc. (Nasdaq: AXNX) has announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for US$71 in cash per share, representing an equity value of approximately US$3.7 billion.
Latham & Watkins LLP represented J.P. Morgan Securities LLC, as financial advisor to Axonics, in the transaction with a corporate deal team led by New York/Orange County partner Charles Ruck and Bay Area partner Luke Bergstrom, with associate Eric Czubiak.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
